Hjem › Multipelt myelom
Kliniske studier for Multipelt myelom rekrutterer i USA
239 studier for Multipelt myelom rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA41 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Chicago, IL22 studier
- Seattle, WA22 studier
- Washington, DC22 studier
- Edison, NJ22 studier
- Miami, FL21 studier
- Salt Lake City, UT21 studier
- Charlotte, NC21 studier
- Milwaukee, WI21 studier
- Queens, NY20 studier
- Detroit, MI19 studier
- Jacksonville, FL18 studier
- Birmingham, AL18 studier
- Los Angeles, CA17 studier
- Dallas, TX17 studier
- Cincinnati, OH17 studier
- Cleveland, OH16 studier
- Phoenix, AZ16 studier
- Philadelphia, PA16 studier
- Omaha, NE16 studier
- Tampa, FL15 studier
- Cedar Rapids, IA15 studier
- San Francisco, CA15 studier
- Irvine, CA14 studier
- Winston-Salem, NC14 studier
- New Rochelle, NY14 studier
- New Haven, CT14 studier
- Clifton, NJ14 studier
- Portland, OR13 studier
- Indianapolis, IN13 studier
Etter delstat
- Alabama22 studier
- Arizona28 studier
- Arkansas9 studier
- California70 studier
- Colorado37 studier
- Connecticut18 studier
- Delaware4 studier
- District of Columbia10 studier
- Florida55 studier
- Georgia49 studier
- Idaho3 studier
- Illinois31 studier
- Indiana19 studier
- Iowa17 studier
- Kansas12 studier
- Kentucky15 studier
- Louisiana9 studier
- Maine3 studier
- Maryland25 studier
- Massachusetts44 studier
- Michigan26 studier
- Minnesota30 studier
- Missouri27 studier
- Montana4 studier
- Nebraska18 studier
- New Hampshire4 studier
- New Jersey38 studier
- New Mexico5 studier
- New York75 studier
- North Carolina52 studier
- North Dakota5 studier
- Ohio46 studier
- Oklahoma3 studier
- Oregon20 studier
- Pennsylvania23 studier
- Rhode Island6 studier
- South Carolina9 studier
- South Dakota3 studier
- Tennessee32 studier
- Texas53 studier
- Utah21 studier
- Virginia20 studier
- Washington30 studier
- West Virginia3 studier
- Wisconsin28 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RekruttererFase 1
Alder 18 til 120 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06904066A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07582432A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07589634A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
RekruttererFase 2
Alder 60 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06679829Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06630104Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06948084The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07285044A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05519085SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07850284A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05652335A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT04973605Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RekruttererObservasjonsstudie
Alder 18 til 120 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT02682667Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RekruttererFase 2
Alder 18 til 72 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT03412877Tissue Collection for Studies of Lymph Cancer
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT01676805A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06500884A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07073547A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06768489Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07609940A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07149857A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07258511Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
RekruttererFase 2
Alder 60 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06052826A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT04634552Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.